Back to Home Review Finds Brain Tumour Patients Harmed by Prolonged Chemotherapy at English Hospital Trust Health

Review Finds Brain Tumour Patients Harmed by Prolonged Chemotherapy at English Hospital Trust

Published on November 19, 2026 5 views

An independent review published on Wednesday found that brain tumour patients at University Hospitals Coventry and Warwickshire NHS Trust in England received prolonged chemotherapy without evidence of benefit, and some suffered severe harm. The Royal College of Physicians examined 20 cases: it rated 15 patients’ care unsatisfactory and said the other five cases required improvement.

The trust commissioned the review after clinicians raised concerns when patients of a consultant oncologist were transferred to colleagues following his retirement in 2023. The trust identified the retired doctor as Professor Ian Brown. The findings concern care in the trust’s neuro-oncology service, rather than all cancer treatment at its hospitals.

Reviewers found repeated long courses of temozolomide, a chemotherapy medicine used for some brain tumours, beyond accepted guidance. In some cases treatment continued despite worsening disease or toxic effects, with little or no evidence of benefit. The review found that six of the 20 patients suffered severe harm, five moderate harm and eight lower levels of harm; it could not settle the harm grade in one case.

The report also described insecure diagnoses and inadequate information for patients deciding whether to continue treatment. In one reviewed case, a patient received chemotherapy for more than 10 years after being told they had a deadly glioblastoma; reviewers later identified a low-grade tumour that did not require chemotherapy. The review found that clinical oversight and opportunities to challenge unusual prescribing had failed.

Trust chief executive Andy Hardy and chair Sue Noyes apologised to patients and families, acknowledged that treatment went beyond national guidance and said the trust had strengthened oversight. The trust said it had extended its historical review back to 2005 and had already reviewed the care of living patients currently receiving temozolomide internally.

The Royal College of Physicians recommended independent reviews for every living patient who received more than 12 cycles of the drug and consideration of whether deceased patients’ cases also need examination. Law firm Brabners, which represents more than 40 people concerned about their care, called for a public inquiry. The 20 cases reviewed do not establish how many patients in total were affected.

Sources: The Guardian (https://www.theguardian.com/society/2026/nov/18/cancer-patients-nhs-trust-unnecessary-chemotherapy-coventry); ITV News/PA Media (https://www.itv.com/news/2026-11-18/patients-severely-harmed-and-left-on-chemotherapy-for-years-at-nhs-trust); Royal College of Physicians review via University Hospitals Coventry and Warwickshire NHS Trust (https://www.uhcw.nhs.uk/contact-us/did-we-get-it-right/neuro-oncology-support/); Brabners patient representatives (https://www.brabners.com/insights/medical-negligence-serious-personal-injury/time-for-a-public-inquiry-rcp-report-reveals-scale-of-coventry-cancer-care-failings)

Comments